Tapan Kanti Das

Title: Tapan Kanti Das: Innovator in Antibody Compositions and Diabetes Treatment

Introduction

Tapan Kanti Das is a notable inventor based in Ballwin, MO (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel antibody compositions and treatments for diabetes. With a total of 2 patents, his work has the potential to impact various medical conditions.

Latest Patents

One of Tapan's latest patents is titled "Anti-CTLA-4 antibody compositions." This invention provides novel compositions of anti-CTLA-4 antibodies that include a chelating agent. The patent also outlines methods for treating diseases and conditions associated with CTLA-4 antibodies, particularly various neoplasia conditions. Another significant patent is "FGF21 conjugates and anti-diabetic uses thereof." This invention describes a FGF21 molecule that is covalently attached to the combining site of an antibody via a linker. The patent details various uses of these compounds, including methods to prevent or treat diabetes and diabetes-related conditions.

Career Highlights

Throughout his career, Tapan Kanti Das has worked with prominent companies in the biotechnology sector. Notably, he has been associated with Pfizer Corporation and Covx Technologies Ireland Limited. His experience in these organizations has contributed to his expertise in developing innovative medical solutions.

Collaborations

Tapan has collaborated with several professionals in his field, including Justin Abate and Kevin Muthurania. These collaborations have likely enhanced his research and development efforts, leading to his successful patent applications.

Conclusion

Tapan Kanti Das is a distinguished inventor whose work in antibody compositions and diabetes treatment showcases his innovative spirit. His contributions to biotechnology are significant and hold promise for future medical advancements.